• Recommended phase II dose of sorafenib tosylate when given in combination with cytarabine (Phase I) [ Designated as safety issue: Yes ]
• Dose-limiting toxicity (Phase I) [ Designated as safety issue: Yes ]
• Complete remission (Phase II) [ Designated as safety issue: No ]

• Recommended phase II dose of daily oral sorafenib tosylate when given in combination with cytarabine (Phase I)
• Dose-limiting toxicity (Phase I)
• Complete remission (Phase II)

• Overall response rate (complete and partial response) (Phase II) [ Designated as safety issue: No ]
• Time to progression (Phase II) [ Designated as safety issue: No ]
• Overall survival (Phase II) [ Designated as safety issue: No ]
• Transfusion dependence (Phase II) [ Designated as safety issue: No ]
• Toxicity (Phase II) [ Designated as safety issue: Yes ]

• Overall response rate (complete and partial response) (Phase II)
• Time to progression (Phase II)
• Overall survival (Phase II)
• Transfusion dependence (Phase II)
• Toxicity (Phase II)

RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with cytarabine may kill more cancer cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of giving sorafenib together with cytarabine and to see how well it works in treating older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

OBJECTIVES:

• To determine the recommended dose of sorafenib tosylate and cytarabine when given in combination to elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndromes who are not suitable for intensive chemotherapy. (Phase I)
• To determine the safety, tolerability, toxicity profile, and dose-limiting toxicities in patients treated with this regimen. (Phase I)
• To estimate the efficacy (as measured by complete response rate) in patients treated with this regimen. (Phase II)
• To describe the toxic effects and overall response rate (complete and partial) in patients treated with this regimen. (Phase II)
• To evaluate potential correlates of response in translational research studies including FLT-3 internal tandem duplications and point mutations in blasts. (Phase II)

OUTLINE: This is a multicenter study.

• Phase I: Patients receive oral sorafenib tosylate twice daily on days 2-28 and cytarabine subcutaneously twice daily on days 1-10 at the dose level assigned at registration. Doses of both drugs will be escalated and the recommended doses for the combination will be determined. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
• Phase II: Patients receive sorafenib tosylate and cytarabine as in phase I at the recommended doses for the combination determined in phase I.

Bone marrow (or blood) samples are collected at baseline and at the end of each course of study treatment. Baseline samples are analyzed for mutational status of FLT-3 (i.e., internal tandem duplication [ITD] and point mutations).

After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 47 will be accrued for this study.

• Leukemia
• Myelodysplastic Syndromes

• Drug: cytarabine
• Drug: sorafenib tosylate
• Genetic: mutation analysis
• Other: laboratory biomarker analysis
• Procedure: biopsy

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

  • Acute myeloid leukemia (AML) by FAB criteria*
  • High-risk myelodysplastic syndromes defined as IPSS category of intermediate-2 or greater NOTE: *By morphology and routine histochemistry and confirmed, when possible, by flow cytometric analysis of surface immunophenotype; co-expression of lymphoid markers permitted
• Must be considered unsuitable for intensive chemotherapy regimens
• No documented CNS involvement

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• AST and ALT ≤ 2 times upper limit of normal (ULN)
• Bilirubin normal
• Creatinine ≤ 1.2 times ULN OR creatinine clearance ≥ 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history of other malignancies, except adequately treated nonmelanoma skin cancer, curatively treated in situ carcinoma of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years
• No upper gastrointestinal or other conditions that would preclude compliance with or administration of oral medication

• No serious illness or medical condition that would not permit the patient to be managed according to the protocol, including any of the following:

  • History of significant neurologic or psychiatric disorder that would impair the ability to obtain consent
  • Active, uncontrolled, serious infections
  • Active peptic ulcer disease
  • Evidence of bleeding diathesis
• No myocardial infarction within the past 6 months
• No congestive heart failure
• No unstable angina
• No active cardiomyopathy or unstable ventricular arrhythmia
• No poorly controlled hypertension (e.g., systolic BP ≥ 150 mm Hg or diastolic BP ≥ 95 mm Hg)
• No known hypersensitivity to the study drugs or their components
• No preexisting hypothyroidism prior to enrollment unless patient is euthyroid on medication
• No neuropathy ≥ grade 2

PRIOR CONCURRENT THERAPY:

• At least 2 days since prior hydroxyurea
• No other prior chemotherapy
• No concurrent oral chemotherapy (e.g., hydroxyurea) to control rapidly rising peripheral blood counts or complications (e.g., bone pain)

• No concurrent therapeutic doses (≥ 2 mg/day) of anticoagulants (e.g., warfarin)

  • Doses of up to 2 mg/day given for prophylaxis of thrombosis are accepted provided INR is ≤ 1.5
• No other concurrent experimental drugs or anticancer therapy
• No other concurrent investigational drugs